Trial Profile
A Phase IIIB, Multi-center, Double-blind, Placebo-controlled, Parallel Group, 52-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol, Administered With DMARDs, in Patients With Low to Moderate Disease Activity Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms CERTAIN
- Sponsors UCB
- 15 Jan 2014 Results published in the Annals of the Rheumatic Diseases.
- 03 Jul 2012 Planned number of patients changed from 170 to 200 as reported by European Clinical Trials Database. (Parent trial: EudraCT2007-000828-40)
- 01 Jun 2012 Results are to be presented at the 13th Annual Congress of the European League Against Rheumatism (EULAR-2012), according to a UCB media release.